Undisclosed Ophthalmology Program
Major Ocular Indication (Unspecified)
Key Facts
About ZipBio
ZipBio is a private, preclinical-stage biotech founded in 2023, pioneering a novel approach to drug discovery through its proprietary COMPACT platform. The platform uses generative AI to design compact, multispecific therapeutic proteins that overcome the size and delivery limitations of traditional biologics, enabling targeting of complex, multi-pathway diseases. The company is building an internal pipeline, with a lead ophthalmology program targeting clinical trials in 2026, and is also exploring external partnerships. Backed by experienced founders and advisors with deep expertise in medicine, protein design, and drug development, ZipBio is positioned at the intersection of AI and biologics to create a new class of smart therapeutics.
View full company profile